SPR Therapeutics closes $37 million in Series D funding


Cleveland medical device company SPR Therapeutics Inc. on Monday, Oct. 18, announced it has raised $37 million to accelerate the development of its neurostimulation platform for pain management, the SPRINT Peripheral Nerve Stimulation (PNS) System.

The company said in a news release that the Series D growth equity financing was led by Revelation Partners, with additional investment from River Cities Capital and Mutual Capital Partners. The investment will bolster what SPR Therapeutics characterized as “the rapidly growing commercial uptake” of the PNS System. It also will “fund additional clinical research” and will “advance next generation technology,” SPR Therapeutics said in the release.

Click here to read the complete story.

Story excerpt provided by Crain’s Cleveland Business.

Written by Scott Suttell.

Originally published October 18, 2021.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: